Medication use among pregnant women is widespread and increasing, according to a recent study from the Boston University School of Public Health in Boston.
Medication use among pregnant women is widespread and increasing, according to a recent study from the Boston University School of Public Health in Boston. The study, which was done in collaboration with the Centers for Disease Control and Prevention (CDC) and the Harvard School of Public Health, also found that medication use varied by socioeconomic status, maternal age, race/ethnicity, and state of residence.
Following are some of the study’s key findings:
1. During the first trimester of pregnancy:
2. Over the last 30 years:
3. Influence of socioeconomic factors:
Findings for the study were obtained from interviews with more than 30,000 women participating in the Boston University’s Slone Epidemiology Center’s Birth Defects Study (1976 to 2008), and the CDC’s National Birth Defects Prevention Study (1997 to 2003). Results included information regarding both prescription and over-the-counter (OTC) drug use.
“Not only is it critical to identify how many OTC and prescription medications are taken by pregnant women and what those specific medications are, but it is also important to know how the use of medications changes over time,” said Allen A. Mitchell, MD, director of Boston University’s Slone Epidemiology Center and a professor of epidemiology.
The researchers note that a number of antenatal medication exposures are known causes of birth defects. However, there is insufficient information about the risks and safety for the vast majority of OTC and prescription medications. This could lead pregnant women to unknowingly take medications that pose a risk to their fetuses. Conversely, anxiety about the potential harm of OTC or prescription medications may discourage pregnant women from adhering to beneficial treatments.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More